Login to Your Account



Ark Set to Move into Phase III Trials with Trinam and Vitor

By Nuala Moran


Wednesday, June 4, 2008
LONDON - Ark Therapeutics plc made significant advances in two of its programs, getting an FDA go-ahead for the Phase III trial of Trinam, a gene-based therapy for preventing blood vessels blocking in vascular access grafts, and securing approval for a European Phase III pilot study of Vitor in treating cancer cachexia. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription